Prevention challenges: The era of atherosclerosis regression

Tardif, Jean‐Claude

doi:10.1016/s0828-282x(06)70999-0

Cited by 4 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combining the HDL-elevating properties of a CETP inhibitor with the LDL cholesterol-lowering properties of a statin may offer improved outcomes over targeting LDL alone. 33 Torcetrapib has been shown to decrease aortic atherosclerosis in animals and significantly increase HDL levels in humans. [34][35][36] However, development of torcetrapib was halted in response to the results of Investigation of Lipid Level management to Understand its iMpact IN ATherosclerosis Events (ILLUMINATE), which showed a 61% increase in all-cause mortality and other cardiovascular events in individuals at high risk for congestive heart disease who were treated with torcetrapib plus atorvastatin compared with those who received placebo plus atorvastatin.…”

Section: Cholesteryl Ester Transfer Protein Inhibitorsmentioning

confidence: 99%

High-density lipoproteins: a novel therapeutic target for cardiovascular disease

Saleem¹,

Rani²,

Gauthaman³

2011

RRCC

View full text Add to dashboard Cite

Cardiovascular disease has a high rate of mortality in both Western and developing countries. Atherosclerosis and generation of reactive oxygen species through oxidative stress is the major risk factor for cardiovascular disease. Atherothrombosis with low levels of high-density lipoprotein (HDL) and high levels of low-density lipoprotein is a major risk factor for atherosclerosis-induced cardiovascular disease. Lipid-lowering drugs like statins, niacin, fibrates, and some newer agents, ie, the apolipoprotein A-I mimetics and the cholesteryl ester transfer protein inhibitors, not only increase HDL levels but are also effective in reducing key atherogenic lipid components, including triglyceride-rich lipoproteins. The aim of this review is to discuss the accumulating evidence suggesting that HDL possesses a diverse range of biological actions, and that increasing HDL levels by drug treatment may be beneficial in the prevention of cardiovascular disease.

show abstract

Section: Cholesteryl Ester Transfer Protein Inhibitorsmentioning

confidence: 99%

High-density lipoproteins: a novel therapeutic target for cardiovascular disease

Saleem¹,

Rani²,

Gauthaman³

2011

RRCC

View full text Add to dashboard Cite

show abstract

“…Statins are of significant benefit in the primary and secondary prevention of atherosclerosis [ 138 ]. Statins slow atherosclerosis progression and can even induce atherosclerosis regression [ 139 ]. Moreover, statins can reduce the level of CETP; see review by Kolovou et al [ 137 ].…”

Section: Managementmentioning

confidence: 99%

“…CETP inhibition appears to be one particularly promising strategy, although they still have some difficulties; see review by Schaefer [ 140 ]. The CETP inhibitor torcetrapib increases plasma HDL cholesterol levels from 40% to 60%, while modestly decreasing LDL cholesterol [ 139 ]. Combining the HDL cholesterol-elevating properties of a CETP inhibitor with the LDL cholesterol-lowering properties of a statin may offer theoretically improved outcomes over targeting LDL cholesterol alone [ 139 ].…”

Section: Managementmentioning

confidence: 99%

“…The CETP inhibitor torcetrapib increases plasma HDL cholesterol levels from 40% to 60%, while modestly decreasing LDL cholesterol [ 139 ]. Combining the HDL cholesterol-elevating properties of a CETP inhibitor with the LDL cholesterol-lowering properties of a statin may offer theoretically improved outcomes over targeting LDL cholesterol alone [ 139 ]. Toth [ 141 ], based on a number of considerations, including the complex relationship between loss of function mutations in CETP and risk for coronary artery disease and the clinical experience with torcetrapib, suggested that it is difficult to predict if CETP inhibition will be associated with reductions in rates of atherosclerosis disease progression and risk for cardiovascular events.…”

Section: Managementmentioning

confidence: 99%

See 1 more Smart Citation

We Are Ageing

Kolovou

Mavrogeni

2014

BioMed Research International

View full text Add to dashboard Cite

Ageing and longevity is unquestioningly complex. Several thoughts and mechanisms of ageing such as pathways involved in oxidative stress, lipid and glucose metabolism, inflammation, DNA damage and repair, growth hormone axis and insulin-like growth factor (GH/IGF), and environmental exposure have been proposed. Also, some theories of ageing were introduced. To date, the most promising leads for longevity are caloric restriction, particularly target of rapamycin (TOR), sirtuins, hexarelin and hormetic responses. This review is an attempt to analyze the mechanisms and theories of ageing and achieving longevity.

show abstract

“…Inhibition of CETP using polyclonal or monoclonal antibodies, or small molecule inhibitors of CETP has been shown to increase HDL-C and reduce the risk of atherosclerosis. [25][26][27] We designed vaccines containing a B-cell epitope identified in the C-terminal 16 amino acids of human CETP. This sequence has been shown to be required for CETP function, and it binds several CETP-neutralizing monoclonal antibodies.…”

Section: Vaccines To Molecules Involved In Cholesterol Metabolismmentioning

confidence: 99%

Vaccines for Cholesterol Management

Rittershaus

2007

World j. surg.

View full text Add to dashboard Cite

Over the last 50 years, several attempts have been made to harness the power and economy of vaccines in the fight against cardiovascular disease. Vaccines directed to lipoproteins, cholesterol itself, and molecules involved in cholesterol metabolism have all demonstrated success in modifying progression of disease in animal models of atherosclerosis. One vaccine that elicits antibodies to cholesteryl ester transfer protein has also progressed into the realm of human clinical testing. This review summarizes the published scientific work describing the various approaches that have been tried, their strengths and weaknesses, and where this field may go in the future.

show abstract

Prevention challenges: The era of atherosclerosis regression

Cited by 4 publications

References 42 publications

High-density lipoproteins: a novel therapeutic target for cardiovascular disease

High-density lipoproteins: a novel therapeutic target for cardiovascular disease

We Are Ageing

Vaccines for Cholesterol Management

Contact Info

Product

Resources

About